VINTOR 4000

Vintor 4000IU injection contains Recombinant human erythropoietin alfa/epoetin alfa, an active component classified as an erythropoiesis-stimulating agent (ESA). This medication is primarily used to treat anemia that arises from chronic kidney disease (CKD), cancer chemotherapy, or in patients undergoing treatment for HIV infection with zidovudine. Beyond managing anemia, it also plays a crucial role in reducing the necessity for red blood cell transfusions in patients facing a high risk of blood loss due to scheduled surgery or other medical procedures.

However, the use of Vintor 4000IU injection is contraindicated in several patient populations. It should not be administered to individuals with known hypersensitivity to the drug or any of its components, those with uncontrolled hypertension, active thrombotic microangiopathy (TMA), pure red cell aplasia (PRCA), uncontrolled seizures, or in pregnant or lactating women. Caution is advised when considering this medication for patients with a history of blood clots, heart disease, stroke, kidney disease, liver disease, thalassemia, sickle cell anemia, myelodysplastic syndrome, leukemia, or cancer. For children under 18 years of age, Vintor 4000IU injection should only be used if the potential benefits unequivocally outweigh the associated risks. Older adults receiving this medication require particularly close monitoring for potential side effects. Prior to initiating treatment with Vintor 4000IU injection, it is essential to have a thorough discussion with your doctor to fully understand both the potential risks and benefits of this medication.